A practical reference on peptide hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-02. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
== History == The discovery and characterization of aminopeptidases date back to the early 20th century. The term "aminopeptidase" was first introduced in 1929 by Linderstrøm-Lang and Sato in order to describe enzymes that cleave amino acids from the N-terminus of peptides. In the 1950s and 1960s, the discovery of leucine aminopeptidase (LAP) and aminopeptidase N (APN) marked important milestones in the field. LAP was found to be crucial for protein digestion, while APN was recognized for its role in the regulation of peptide-mediated effects. These discoveries were pivotal in understanding the physiological functions of aminopeptidases and their involvement in health and disease. The subsequent decades saw extensive research into the structure, function, and mechanisms of action of various aminopeptidases. For example, the M1 family of aminopeptidases, which includes puromycin-sensitive aminopeptidase (PSA), was characterized by conserved zinc-dependent sites and exopeptidase motifs. The study of PSA in different model organisms revealed its essential roles in growth and behavior. Mutations in orthologs of PSA in different species were linked to errors in meiosis and reduced viability of embryos. Aminopeptidase N, also known as AP-N or CD13, was extensively characterized for its broad substrate specificity (ability to bind to its targets) and its presence in various tissues such as the brush border membranes of the kidney, small intestine, and placenta.
There are several strategies for removal and/or negation of ion suppression. These approaches may require in-depth understanding of the ionisation mechanisms involved in different ionisation sources or may be completely independent of the physical factors involved.
Starting in April 1978, all free-ranging mustangs and burros rounded up by the BLM or the U.S. Forest Service have been freeze branded on the left side of the neck using Farrell's Alpha-Angle system. This is generally done at a short-term holding facility along with basic medical care like vaccination and deworming. Captured mustangs then enter the BLM's adoption program. Capture, branding, medical screening and adoption have long been the preferred means of controlling feral horse populations in the US. So efficient is Farrell's system and so successful was this tagging project that since the early 1980s it has become extremely rare to run across an adult mustang without a freeze brand. The BLM uses the following sequence for identification:
Sources: en.wikipedia.org
=== Erectile dysfunction === The primary indication of sildenafil is treatment of erectile dysfunction (inability to sustain a satisfactory erection to complete sexual intercourse). Its use is now one of the standard treatments for erectile dysfunction, including for males with diabetes mellitus. Tentative evidence suggests that sildenafil may help males who experience antidepressant-induced erectile dysfunction.
The four substrates of this enzyme are 4-nitrocatechol, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are hydroxy-1,4-benzoquinone, oxidised NAD+, water, and nitrous acid. It is a flavoprotein that uses flavin adenine dinucleotide as a cofactor.
H+ + N−3 → HN3 Hydrazoic acid, which is also extremely toxic, is especially dangerous because it is a volatile liquid at room temperature. Otherwise, aqueous solutions contain only minute amounts of hydrazoic acid, as described by the following equilibrium reaction:
Psilocybin can rarely cause hallucinogen-induced psychotic disorder (HIPD). In one study, psilocybin was responsible for 18.8% of cases of HIPD caused by psychedelics. Hallucinogen-induced psychotic disorder is a type of substance-induced psychosis where paranoia, delusions, hallucinations, or a thought disorder persist beyond the hallucinogen's initial effects. HIPD due to psychedelics is most commonly caused by LSD use, but can be caused by psilocybin as well. Hallucinogen-induced psychotic disorder is a medical emergency. Without treatment, a psychotic state can persist for weeks or months. The treatment is an atypical antipsychotic medication such as aripiprazole, quetiapine, olanzapine, or risperidone. People with personal or family histories of psychiatric disorders are at the highest risk for hallucinogen-induced psychotic disorder. The condition occurs in fewer than 1% of people who use psychedelics.
Sources: en.wikipedia.org
Spectroscopy measures the interaction of the molecules with electromagnetic radiation. Spectroscopy consists of many different applications such as time-resolved raman spectroscopy, atomic absorption spectroscopy, atomic emission spectroscopy, ultraviolet-visible spectroscopy, X-ray spectroscopy, fluorescence spectroscopy, infrared spectroscopy, Raman spectroscopy, dual polarization interferometry, nuclear magnetic resonance spectroscopy, photoemission spectroscopy, Mössbauer spectroscopy and so on.
=== Religious opposition === A number of religious sects prohibit organ donation. Ultra-Orthodox Jews oppose post mortem organ donation, and have tried to pass laws against unclaimed cadavers being used in research. A number of religious organizations, including Catholic and Jewish ones, object to the display of plastinated body parts at public exhibitions.
Protons are spin-1/2 fermions and are composed of three valence quarks, making them baryons (a sub-type of hadrons). The two up quarks and one down quark of a proton are held together by the strong force, mediated by gluons. A modern perspective has a proton composed of the valence quarks (up, up, down), the gluons, and transitory pairs of sea quarks. Protons have a positive charge distribution, which decays approximately exponentially, with a root mean square charge radius of about 0.8 fm. Protons and neutrons are both nucleons, which may be bound together by the nuclear force to form atomic nuclei. The nucleus of the most common isotope of the hydrogen atom (with the chemical symbol "H") is a lone proton. The nuclei of the heavy hydrogen isotopes deuterium and tritium contain one proton bound to one and two neutrons, respectively. All other types of atomic nuclei are composed of two or more protons and various numbers of neutrons.
== Applications == Cell biology utilizes tools that allow manipulation and visualization of proteins in living cells. An important example is the use of fluorescent proteins, such as the green fluorescent protein (GFP) or yellow fluorescent protein (YFP). Molecular biology methods allow these fluorescent proteins to be introduced and expressed in living cells as fusion proteins. However, the photo-physical properties of the fluorescent proteins are generally not suited for single-molecule spectroscopy. Fluorescent proteins have, in comparison to commercially available dyes, a much lower fluorescence quantum yield and are quickly destroyed upon excitation with a focused laser beam (photobleaching). The SNAP-tag® protein is an engineered version of the ubiquitous mammalian enzyme AGT, encoded in humans by the O-6-methylguanine-DNA methyltransferase (MGMT) gene. SNAP-tag was obtained using a directed evolution strategy, leading to a hAGT variant that accepts O6-benzylguanine derivatives instead of repairing alkylated guanine derivatives in damaged DNA. An orthogonal tag, called CLIP-tag™, was further engineered from SNAP-tag to accept O2-benzylcytosine derivatives as substrates, instead of O6-benzylguanine. Therefore, Clip-tag- and SNAP-tag-fused proteins can be labeled simultaneously in the same cells. A split-SNAP-tag version suitable for protein complementation assay and protein-protein interaction studies was later developed.
== Infrared chemiluminescence == In chemical kinetics, infrared chemiluminiscence (IRCL) refers to the emission of infrared photons from vibrationally excited product molecules immediately after their formation. The intensities of infrared emission lines from vibrationally excited molecules are used to measure the populations of vibrational states of product molecules. The observation of IRCL was developed as a kinetic technique by John Polanyi, who used it to study the attractive or repulsive nature of the potential energy surface for gas-phase reactions. In general the IRCL is much more intense for reactions with an attractive surface, indicating that this type of surface leads to energy deposition in vibrational excitation. In contrast reactions with a repulsive potential energy surface lead to little IRCL, indicating that the energy is primarily deposited as translational energy.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.